+

SMT201500061B - Topi adam6 - Google Patents

Topi adam6

Info

Publication number
SMT201500061B
SMT201500061B SM201500061T SM201500061T SMT201500061B SM T201500061 B SMT201500061 B SM T201500061B SM 201500061 T SM201500061 T SM 201500061T SM 201500061 T SM201500061 T SM 201500061T SM T201500061 B SMT201500061 B SM T201500061B
Authority
SM
San Marino
Prior art keywords
mice6
adam
adam mice6
Prior art date
Application number
SM201500061T
Other languages
English (en)
Inventor
Sean Stevens
Andrew J Murphy
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500061(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT201500061B publication Critical patent/SMT201500061B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SM201500061T 2011-02-25 2015-03-11 Topi adam6 SMT201500061B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
PCT/US2012/026416 WO2012141798A1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (1)

Publication Number Publication Date
SMT201500061B true SMT201500061B (it) 2015-05-05

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
SM20200112T SMT202000112T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM20230173T SMT202300173T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM20190744T SMT201900744T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM20190581T SMT201900581T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM201500061T SMT201500061B (it) 2011-02-25 2015-03-11 Topi adam6

Family Applications Before (4)

Application Number Title Priority Date Filing Date
SM20200112T SMT202000112T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM20230173T SMT202300173T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM20190744T SMT201900744T1 (it) 2011-02-25 2012-02-24 Topi adam6
SM20190581T SMT201900581T1 (it) 2011-02-25 2012-02-24 Topi adam6

Country Status (31)

Country Link
US (12) US8642835B2 (it)
EP (7) EP2738259B1 (it)
JP (8) JP2014507137A (it)
KR (1) KR101387377B1 (it)
CN (2) CN103429746B (it)
AU (5) AU2012243291B2 (it)
BR (1) BR112013021771B1 (it)
CA (1) CA2820824A1 (it)
CY (5) CY1116301T1 (it)
DE (5) DE12192727T1 (it)
DK (6) DK4067496T5 (it)
ES (6) ES2770424T3 (it)
FI (3) FI2738258T4 (it)
HR (5) HRP20150262T1 (it)
HU (5) HUE046081T2 (it)
IL (4) IL226727A (it)
IN (1) IN2013CN07629A (it)
LT (4) LT2738259T (it)
ME (3) ME03732B (it)
MX (3) MX343009B (it)
MY (1) MY172713A (it)
NZ (2) NZ731926A (it)
PL (5) PL2578688T5 (it)
PT (5) PT2738258T (it)
RS (5) RS53880B1 (it)
RU (2) RU2722373C2 (it)
SG (4) SG10201913160QA (it)
SI (5) SI4067496T1 (it)
SM (5) SMT202000112T1 (it)
WO (1) WO2012141798A1 (it)
ZA (1) ZA201305998B (it)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
DK2311874T3 (en) 2004-07-22 2017-08-28 Univ Erasmus Med Ct Rotterdam binding Molecules
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT3241435T (pt) 2009-07-08 2021-08-26 Kymab Ltd Modelos animais e moléculas terapêuticas
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RU2571205C2 (ru) 2010-02-08 2015-12-20 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CN105753979B (zh) 2010-08-02 2021-05-07 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
ES2770424T3 (es) 2011-02-25 2020-07-01 Regeneron Pharma Ratones ADAM6
CA2841376C (en) 2011-07-05 2023-02-28 Duke University N-terminal deleted gp120 immunogens
EP3572517B1 (en) * 2011-08-05 2021-03-24 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
JP6271435B2 (ja) 2011-10-17 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖のマウス
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR102186822B1 (ko) * 2011-12-20 2020-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
KR20190006029A (ko) * 2012-02-01 2019-01-16 리제너론 파마슈티칼스 인코포레이티드 Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류
HRP20191333T1 (hr) 2012-03-16 2019-10-18 Regeneron Pharmaceuticals, Inc. Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX381210B (es) 2012-03-16 2025-03-12 Regeneron Pharma Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos.
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN108586610A (zh) 2012-04-20 2018-09-28 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
WO2013187953A1 (en) 2012-06-12 2013-12-19 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
SG11201505713YA (en) 2013-02-06 2015-08-28 Regeneron Pharma B cell lineage based immunogen design with humanized animals
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
EP2967012B1 (en) * 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
EP3119194B1 (en) * 2014-03-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR102482103B1 (ko) 2016-01-13 2022-12-28 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
MA44242A (fr) 2016-02-16 2018-12-26 Regeneron Pharma Animaux non humains ayant un gène de kynuréninase mutant
EP3457840B1 (en) * 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
RU2753585C2 (ru) 2016-06-03 2021-08-18 Регенерон Фармасьютикалз, Инк. Животные, не являющиеся человеком, экспрессирующие экзогенную терминальную дезоксинуклеотидилтрансферазу
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
SI3766343T1 (sl) * 2016-11-04 2022-06-30 Regeneron Pharmaceuticals, Inc. Nehumane živali z modificiranim lokusom lahke verige lambda imunoglobulina
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
MX2020008274A (es) 2018-02-07 2020-11-11 Regeneron Pharma Metodos y composiciones para la administracion de proteinas terapeuticas.
US20210000088A1 (en) 2018-03-21 2021-01-07 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
CN116874591A (zh) 2018-03-24 2023-10-13 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
KR20210004994A (ko) 2018-03-26 2021-01-13 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
MX2021009855A (es) 2019-02-22 2021-09-10 Regeneron Pharma Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
DK3785536T3 (da) * 2019-08-28 2022-03-28 Trianni Inc Adam6-knockin-mus
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma Peptide-mhc ii protein constructs and uses thereof
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途
TW202242114A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法
AU2022261074A1 (en) 2021-04-20 2023-09-28 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
MA71452A (fr) 2022-07-12 2025-04-30 Regeneron Pharmaceuticals, Inc. Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
HUT71790A (en) * 1992-12-01 1996-02-28 Protein Design Labs Humanized antibodies reactive with l-selectin
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
WO2000073323A2 (en) * 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1391511B1 (en) * 2001-05-11 2008-06-11 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody lambda light chain gene
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
EP1739691B1 (en) 2005-06-30 2008-12-03 Borealis Technology Oy Outer sheath layer for power or communication cable
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2041177T3 (da) 2006-06-02 2012-02-27 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
PT3241435T (pt) * 2009-07-08 2021-08-26 Kymab Ltd Modelos animais e moléculas terapêuticas
SMT201900251T1 (it) 2009-12-10 2019-07-11 Regeneron Pharma Topi che producono anticorpi della catena pesante
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RU2571205C2 (ru) 2010-02-08 2015-12-20 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
ES2770424T3 (es) 2011-02-25 2020-07-01 Regeneron Pharma Ratones ADAM6
EP3572517B1 (en) 2011-08-05 2021-03-24 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
JP6271435B2 (ja) 2011-10-17 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限定された免疫グロブリン重鎖のマウス
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR102186822B1 (ko) 2011-12-20 2020-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
WO2013187953A1 (en) 2012-06-12 2013-12-19 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci

Also Published As

Publication number Publication date
NZ612643A (en) 2015-06-26
DK2738258T4 (da) 2023-05-08
IL268671A (en) 2019-10-31
EP2578688B2 (en) 2023-02-08
HUE047687T2 (hu) 2020-05-28
AU2017251802A1 (en) 2017-11-16
US20180346598A1 (en) 2018-12-06
EP2738259A3 (en) 2014-07-30
HK1201292A1 (en) 2015-08-28
ME03732B (me) 2021-01-20
SG10201913160QA (en) 2020-03-30
EP2738259A2 (en) 2014-06-04
ZA201305998B (en) 2016-07-27
PL2550363T3 (pl) 2015-05-29
CN103429746A (zh) 2013-12-04
US10905109B2 (en) 2021-02-02
US8697940B2 (en) 2014-04-15
SMT201900744T1 (it) 2020-01-14
RS64280B1 (sr) 2023-07-31
CN103429746B (zh) 2016-05-11
EP2550363B1 (en) 2014-12-10
CY1122459T1 (el) 2021-01-27
DK4067496T5 (da) 2024-07-22
SMT201900581T1 (it) 2019-11-13
NZ731926A (en) 2021-07-30
PT2738259T (pt) 2020-02-18
US20180345760A1 (en) 2018-12-06
BR112013021771B1 (pt) 2022-11-16
EP2578688A1 (en) 2013-04-10
HUE062552T2 (hu) 2023-11-28
DK4067496T3 (da) 2023-06-26
DE12716101T1 (de) 2013-05-08
US20240306617A1 (en) 2024-09-19
JP2014507137A (ja) 2014-03-27
ES2946169T3 (es) 2023-07-13
CY1122820T1 (el) 2021-05-05
DK2738258T1 (da) 2014-11-24
EP2738258B1 (en) 2019-09-25
PT2738258T (pt) 2019-12-10
DK2578688T3 (da) 2019-10-28
IL268671B (en) 2020-05-31
US20210105984A1 (en) 2021-04-15
PT2550363E (pt) 2015-03-16
CA2820824A1 (en) 2012-10-18
IL273986A (en) 2020-05-31
PL2738258T3 (pl) 2020-08-24
EP2550363A1 (en) 2013-01-30
HRP20192311T4 (hr) 2023-05-12
SI2738258T1 (sl) 2020-01-31
DK2738259T1 (da) 2014-11-24
JP2015107131A (ja) 2015-06-11
RU2722373C2 (ru) 2020-05-29
US8642835B2 (en) 2014-02-04
SG10201913155QA (en) 2020-02-27
LT2738258T (lt) 2020-01-10
SMT202000112T1 (it) 2020-05-08
US20150201589A1 (en) 2015-07-23
US9932408B2 (en) 2018-04-03
PL2578688T5 (pl) 2023-05-29
IN2013CN07629A (it) 2015-08-07
ES2770424T3 (es) 2020-07-01
MX2020009714A (es) 2020-10-07
DE14154918T1 (de) 2014-08-21
RS59929B1 (sr) 2020-03-31
LT2578688T (lt) 2019-11-11
SI2738259T1 (sl) 2020-06-30
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
ES2748832T3 (es) 2020-03-18
DK2550363T3 (en) 2015-03-23
CY1116301T1 (el) 2017-02-08
DK2738258T3 (da) 2019-12-16
IL226727A (en) 2016-08-31
HRP20230526T1 (hr) 2023-09-01
HRP20200294T1 (hr) 2020-05-29
HRP20191895T1 (hr) 2020-01-10
ME03537B (it) 2020-04-20
BR112013021771A2 (pt) 2017-07-04
KR101387377B1 (ko) 2014-04-21
CY1126091T1 (el) 2023-11-15
ME02106B (me) 2015-10-20
EP2813573B1 (en) 2020-04-22
SI2578688T2 (sl) 2023-05-31
PL2578688T3 (pl) 2020-05-18
AU2022206806A1 (en) 2022-08-18
SI2738258T2 (sl) 2023-05-31
PL2738259T3 (pl) 2020-08-24
IL261243A (en) 2018-10-31
AU2012243291A1 (en) 2013-05-09
HRP20191895T4 (hr) 2023-05-12
US10577430B2 (en) 2020-03-03
MX343009B (es) 2016-10-21
RU2016109443A (ru) 2018-11-26
RU2016109443A3 (it) 2019-07-24
EP2738258A2 (en) 2014-06-04
NZ797720A (en) 2024-09-27
US10905108B2 (en) 2021-02-02
RU2582261C2 (ru) 2016-04-20
FI2738258T4 (fi) 2023-05-05
ES2805364T3 (es) 2021-02-11
WO2012141798A1 (en) 2012-10-18
HK1174490A1 (en) 2013-06-14
JP2019187446A (ja) 2019-10-31
JP2025032218A (ja) 2025-03-11
EP3744850A1 (en) 2020-12-02
LT4067496T (lt) 2023-06-12
JP5866127B2 (ja) 2016-02-17
CN105861548A (zh) 2016-08-17
AU2020201279A1 (en) 2020-03-12
IL273986B (en) 2021-04-29
EP2738259B1 (en) 2019-11-27
MY172713A (en) 2019-12-11
RS53880B1 (en) 2015-08-31
HUE024534T2 (hu) 2016-01-28
US20130254911A1 (en) 2013-09-26
RS59413B2 (sr) 2023-06-30
US20150210776A1 (en) 2015-07-30
NZ703609A (en) 2016-04-29
JP2018143250A (ja) 2018-09-20
RS59413B1 (sr) 2019-11-29
EP2738258B2 (en) 2023-02-01
DE14154967T1 (de) 2014-08-28
EP4067496A1 (en) 2022-10-05
KR20130116375A (ko) 2013-10-23
AU2015238806A1 (en) 2015-10-29
US9944716B2 (en) 2018-04-17
FI4067496T3 (fi) 2023-05-24
HUE046746T2 (hu) 2020-03-30
CN105861548B (zh) 2020-01-10
LT2738259T (lt) 2020-03-10
ES2758974T5 (es) 2023-06-08
US10072095B2 (en) 2018-09-11
NZ718688A (en) 2017-07-28
JP2014110814A (ja) 2014-06-19
HRP20150262T1 (hr) 2015-04-10
JP2016135143A (ja) 2016-07-28
EP2813573A1 (en) 2014-12-17
ES2748832T5 (es) 2023-06-08
SI4067496T1 (sl) 2023-07-31
SG192933A1 (en) 2013-09-30
US20180362663A1 (en) 2018-12-20
US20120322108A1 (en) 2012-12-20
DE14176593T1 (de) 2015-03-05
MX375115B (es) 2025-03-06
IL261243B (en) 2019-08-29
EP2738258A3 (en) 2014-09-24
US12207628B2 (en) 2025-01-28
RS59661B1 (sr) 2020-01-31
EP4067496B1 (en) 2023-03-29
AU2012243291B2 (en) 2015-07-09
US20210105985A1 (en) 2021-04-15
SG10201405135RA (en) 2014-10-30
ES2758974T3 (es) 2020-05-07
SMT202300173T1 (it) 2023-07-20
ES2532487T3 (es) 2015-03-27
DK2813573T1 (da) 2015-01-12
DK2578688T4 (da) 2023-05-08
RS59661B2 (sr) 2023-06-30
CY1122205T1 (el) 2020-11-25
NZ776770A (en) 2023-03-31
PT4067496T (pt) 2023-06-07
HUE046081T2 (hu) 2020-01-28
DK2738259T3 (da) 2020-02-17
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
MX2013009649A (es) 2013-09-26
SI2578688T1 (sl) 2019-11-29
DE12192727T1 (de) 2013-07-11
US20180346599A1 (en) 2018-12-06
JP2022071051A (ja) 2022-05-13
RU2013125717A (ru) 2014-12-10
US10694725B2 (en) 2020-06-30
EP2578688B1 (en) 2019-07-24
FI2578688T4 (fi) 2023-05-05
US20140213773A1 (en) 2014-07-31
DK2578688T1 (da) 2014-11-24
HRP20192311T1 (hr) 2020-03-20
PL4067496T3 (pl) 2023-07-31

Similar Documents

Publication Publication Date Title
SMT201500061B (it) Topi adam6
DK2679008T3 (da) Multi-metrik filtrering
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2768410A4 (en) EXTENSION COLLAR SYSTEM
DK2769050T3 (da) Propsensor
EP2748335A4 (en) BIOLOGICAL MARKERS OF URINE
PL2663506T3 (pl) Zamknięcie
DE102011100082A8 (de) Traygreifvorrichtung
BR112014000879A2 (pt) deflegmador
EP2744428A4 (en) TROKARTRÄGER
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
EP2786752A4 (en) Ropinirole-containing adhesive patch
DK3141251T3 (da) Koloskopi - forberedelse
EP2708561A4 (en) BIO-PIN
EP2738148A4 (en) RECIPROCAL LOCKING BLOCK
DE112011104936A5 (de) Stanzstauchniet
EP2760803A4 (en) Geopolymer product
EP2788163A4 (en) POST-MOLDING SYSTEM
EP2729467A4 (en) CRYPTATE COMPOUNDS
EP2698098A4 (en) campimeter
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012005313A5 (de) Leuchtbild
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载